Delivery Order SPE2DB22D3301-SPE2DB26FX3SF
- Not listed
- The Defense Logistics Agency awarded a $5,590.59 delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Orencia 125 mg/ml syringes. This competitively awarded, firm fixed-price contract is not set-aside and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. Performance will be executed from the contractor's location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for $3,570.63 on July 14, 2025, for the supply of Orencia 125 mg/ml syringes. This firm fixed price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a $37,093.95 firm fixed-price delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Orencia ClickJect 125 mg/ml. The contract, which is a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX valued at $999,999,999.00 through December 2026), requires performance completion by October 23, 2025. This delivery order was competitively awarded with no set-aside designation...
- The U.S. Defense Logistics Agency (DLA) Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 28, 2025, for the supply of Orencia 125 mg/ml syringes, valued at $15,917.19 with firm fixed pricing. This competitive award, which carries no set-aside designation, is classified as a delivery order under a larger contract vehicle and is scheduled for completion by August 29, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will fulfill this order...
- The Defense Logistics Agency awarded a $32,269.35 delivery order to AmerisourceBergen Drug Corp for Orencia 125 mg/mL syringes, with an ultimate completion date of October 23, 2025. The contract utilizes a firm fixed price structure with no set-aside designation, indicating competitive award through open procurement. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, serves as a critical pharmaceutical distributor for federal medical procurement, particularly supporting military and...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Orencia 125 mg/mL syringes, valued at $3,701.46. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitively awarded contract. The place of performance is located in Conshohocken, Pennsylvania, with an ultimate completion date of August 20, 2025. This delivery order represents a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Orencia 250 mg vials, a pharmaceutical product used in immunological treatment. This firm fixed-price delivery order, valued at $2,141.91, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The contract was...
- The U.S. Defense Department's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 9, 2025, for the supply of Orencia 125 mg/mL syringes valued at $14,877.38. This is a firm fixed-price delivery order with an ultimate completion date of September 10, 2025. The award was competitively procured with no set-aside designation, reflecting AmerisourceBergen's established capability to meet federal pharmaceutical procurement standards. The contract is performed from...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 7, 2025, for the supply of Orencia 125 mg/ml syringes valued at $8,772.35 with a firm fixed price structure. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999.99 billion prime vendor agreement extending through December 2026. The contract carries no set-aside designation and was...
- AmerisourceBergen Drug Corp, a leading pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a delivery order from the Defense Logistics Agency (DLA) for Orencia 125 mg/mL syringes valued at $8,646.31. The award was made on July 31, 2025, with an ultimate completion date of August 1, 2025, under firm fixed pricing with no set-aside designation. This delivery order represents a competitively awarded transaction processed through the company's existing Indefinite...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB26FX3SFDelivery Order
The Defense Logistics Agency awarded a $70,485.61 delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Orencia 125 mg/ml syringes. This competitively awarded, firm fixed-price contract has an ultimate completion date of October 23, 2025, and carries no set-aside designation. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate headquarters. This delivery order is a child contract issued under AmerisourceBergen's broader Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, a $999.99 billion prime vehicle running through December 2026 that enables the contractor to supply pharmaceutical products and medical supplies to support military healthcare programs globally. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement needs across the Department of Defense and Veterans Affairs healthcare systems. The company's extensive federal contract portfolio demonstrates its capability to deliver a wide range of pharmaceutical products, including specialty medications, brand-name and generic drugs, and medical supplies across multiple therapeutic domains. This order for Orencia—a biologic immunosuppressant used in rheumatoid arthritis treatment—reflects the contractor's role in supplying essential pharmaceutical therapies to military and federal healthcare beneficiaries. The DLA has indicated plans to establish next-generation Pharmaceutical Prime Vendor Global Program Generation V contracts with multiple regional awards, positioning AmerisourceBergen among the anticipated qualified contractors for continued pharmaceutical supply support.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $70.5k | 10/22/25 |